Amerikanische Gesellschaft für Hirudotherapie

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Research article published in The Annals of pharmacotherapy (2004)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienHeuts et al. · The Annals of pharmacotherapy, 2004

Abstract

OBJECTIVE: To review current data regarding low-molecular-weight heparin (LMWH) use for perioperative anticoagulation in patients receiving chronic warfarin therapy. DATA SOURCES: Data were obtained from the Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy guidelines and a MEDLINE search (1996-January 2003). Search terms included heparin, low-molecular-weight heparin, warfarin, perioperative care, and anticoagulants. DATA SYNTHESIS: Heparin is the most common agent used as bridge therapy for perioperative anticoagulation in patients on chronic warfarin therapy; LMWHs are also used. Studies that evaluated enoxaparin and/or dalteparin were reviewed. CONCLUSIONS: Although published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsClinical Trials as TopicFibrinolytic AgentsHeparin, Low-Molecular-WeightHumansPerioperative CareThromboembolismWarfarin

Zusammenfassung

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Warum dies für die Hirudotherapie relevant ist

This review examined current data on low-molecular-weight heparin (LMWH) use for perioperative anticoagulation bridging in patients on chronic warfarin therapy, drawing on ACCP consensus guidelines and a MEDLINE search (1996–2003) covering enoxaparin and dalteparin. It concluded that while published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy. For ASH's domain, the article is relevant only insofar as it concerns anticoagulation management broadly; it does not address leeches, hirudotherapy, or leech-derived anticoagulants. The relevance to hirudotherapy is essentially nil — this is a conventional heparin/warfarin pharmacology review with no leech secretome content. Any interest would be purely contextual, as background on anticoagulant bridging strategies unrelated to leech therapy.

Zitation

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Heuts et al. · The Annals of pharmacotherapy, 2004

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsAnticoagulation CompoundsHemostasisDirect Thrombin InhibitorsOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.